VF
DMAC icon

Virtu Financial’s DiaMedica Therapeutics DMAC Stock Holding History

Virtu Financial’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-15,712
Closed -$159K – 1685
2020
Q4 		$159K Buy
+15,712
New +$86K 0.02% 932

Other funds holding DMAC

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
JAMONY
Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial's DMAC Position: Q1 2021 in Review

Virtu Financial sold out of DiaMedica Therapeutics (DMAC) in Q1 2021, closing a stake of 15,712 shares — an estimated $159K sold.

Virtu Financial first reported a position in DMAC in Q4 2020 and held it in 1 quarter. The position peaked at $159K in Q4 2020. 41 funds tracked by Wall St. Rank hold DMAC as of Q1 2021.

  • Virtu Financial reported no remaining DiaMedica Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Virtu Financial sold 15,712 DiaMedica Therapeutics shares in Q1 2021, an estimated $159K.
  • Virtu Financial first reported a position in DiaMedica Therapeutics in Q4 2020 and held it in 1 quarter.
  • Virtu Financial's DiaMedica Therapeutics position peaked at $159K in Q4 2020.
  • 41 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2021.

Based on Virtu Financial's 13F filing for Q1 2021, filed 19 May 2021.